Tasurgratinib Emerging Drug Insight

“Tasurgratinib Market Size, Forecast, and Emerging Insight – 2032” report provides comprehensive insights about Tasurgratinib for Cholangiocarcinoma (CCA) in the seven major markets. A detailed picture of the Tasurgratinib for Cholangiocarcinoma  in the 7MM, i.e., the United States, EU4 (Germany, France, Italy and Spain) and the United Kingdom, and Japan for the study period 2019–2032 is provided in this report along with a detailed description of the Tasurgratinib for Cholangiocarcinoma .The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Tasurgratinib market forecast, analysis for Cholangiocarcinoma in the 7MM descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Cholangiocarcinoma.

Drug Summary

Discovered in-house by Eisai’s Tsukuba Research Laboratories, Tasurgratinib (E7090) is an orally available novel tyrosine kinase inhibitor that demonstrates selective inhibitory activity against fibroblast growth factor receptors (FGFR) FGFR 1, FGFR 2, and FGFR 3. Distinct from prior known FGFR inhibitors, E7090 has a basic structure which lacks the dimethoxyphenyl moiety, and in a kinetic interaction analysis study, it was observed that E7090 demonstrates anti-tumor effects due to inhibition of kinase activity with a binding mode (Type V) that exhibits rapid and potent binding as well as high selectivity to FGFR.

In a kinetic interaction analysis study, it was observed that E7090 demonstrated anti-tumor effects due to inhibition of kinase activity with a unique binding mode (Type V) that exhibits rapid and potent binding as well as high selectivity to FGFR. FGFRs with genetic aberrations play an essential role in the proliferation, survival, and migration of cancer cells, tumor angiogenesis, and drug resistance. These genetic aberrations in FGFRs have been observed in various types of cancer; therefore, FGFRs are gaining attention as a promising target for cancer therapy. By selectively inhibiting FGFR1, 2, and 3 and blocking those signals, E7090 has the potential to become a new molecular targeted therapy for cancers with FGFR genetic aberrations.

Currently, a Phase II (NCT04238715) clinical trial of E7090 is underway in Japan to evaluate efficacy and safety in patients with cholangiocarcinoma with FGFR2 gene fusion.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the Tasurgratinib description, mechanism of action, dosage and administration, research and development activities in Cholangiocarcinoma.
• Elaborated details on Tasurgratinib regulatory milestones and other development activities have been provided in this report.
• The report also highlights the Tasurgratinib research and development activity in Cholangiocarcinoma in detail across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around Tasurgratinib.
• The report contains forecasted sales of Tasurgratinib for Cholangiocarcinoma till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Cholangiocarcinoma.
• The report also features the SWOT analysis with analyst views for Tasurgratinib in Cholangiocarcinoma.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Tasurgratinib Analytical Perspective by DelveInsight

In-depth Tasurgratinib Market Assessment

This report provides a detailed market assessment of Tasurgratinib in Cholangiocarcinoma in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data of the tasurgratinib.

Tasurgratinib Clinical Assessment

The report provides the clinical trials information of Tasurgratinib in Cholangiocarcinoma covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

• In the coming years, the market scenario for Cholangiocarcinoma is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Tasurgratinib dominance.
• Other emerging products for Cholangiocarcinoma are expected to give tough market competition to Tasurgratinib and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Tasurgratinib in Cholangiocarcinoma.
• Our in-depth analysis of the forecasted sales data the tasurgratinib will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Tasurgratinib in Cholangiocarcinoma.

Key Questions

• What is the product type, route of administration and mechanism of action of Tasurgratinib?
• What is the clinical trial status of the study related to Tasurgratinib in Cholangiocarcinoma and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Tasurgratinib development?
• What are the key designations that have been granted to Tasurgratinib for Cholangiocarcinoma?
• What is the forecasted market scenario of Tasurgratinib for Cholangiocarcinoma?
• What are the forecasted sales of Tasurgratinib in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
• What are the other emerging products available in Cholangiocarcinoma and how are they giving competition to Tasurgratinib for Cholangiocarcinoma?
• Which are the late-stage emerging therapies under development for the treatment of Cholangiocarcinoma?